JPT Peptide Technologies is a peptide product & service company for innovative peptide based products and one of the largest custom peptide vendors worldwide. All of our production and services are performed in our state of the art laboratories in Berlin, Germany according to DIN ISO 9001:2015 and GCLP regulations.
We manufacture high quality peptide products such as:
- Custom peptides
- Modified & Labeled Peptides
- Clinical Peptides
- Stable isotope-labeled peptides
- SPOT peptides
- Immunogenic peptides
- Peptides with post-translational modifications, fluorescence labels,biotin or other modifications
- Peptide libraries
- Peptide pools
- Peptide microarrays
- Peptide ELISA
- Enzyme profiling service
- Epitope discovery service
Please click on your field of interest to jump to a product overview.
Based on technological superiority, long term track record and ISO 9001:2015 regulated production, JPT is the quality leader on custom peptides & peptide microarrays worldwide.
Our products and services are applicable to all developmental phases of cell therapy and immunotherapy, e.g. clinical grade peptides and peptide pools for immune monitoring.
Find products and services for immune monitoring, antigen-specific T-cell stimulation, epitope discovery & mapping, vaccine & immunotherapy development and more.
Learn more about our low price heavy labeled peptides and kits used by leading proteomics labs all over the world. Modifications, isotope labeling, peptide pooling, absolute quantification and many more options.
You have the ideas, we offer the tools to learn more about your enzyme. Find or optimize substrates, identify key residues and consensus sequences, screen for binding partners.
JPT's broad portfolio of peptide based products and services target a variety of indications with a focus on cancer as well as infectious and autoimmune diseases.
Check our list of products,
click and go.
SARS COV-2 Mass Spec Reference Kit Released!
SARS-CoV-2 SpikeMix™ for Mass Spectrometry covers spike, NCAP, VME-1 & ORF9B
Study SARS CoV-2
Cross Reactive T-Cells with EMPS-Peptides from Endemic HCoV’s